Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Decreases By 5.6%

Kronos Bio, Inc. (NASDAQ:KRONGet Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 674,500 shares, a drop of 5.6% from the September 30th total of 714,200 shares. Based on an average daily volume of 87,800 shares, the short-interest ratio is currently 7.7 days. Currently, 1.7% of the shares of the company are sold short.

Kronos Bio Stock Up 3.2 %

Shares of Kronos Bio stock traded up $0.03 during trading on Thursday, reaching $0.97. The company’s stock had a trading volume of 25,438 shares, compared to its average volume of 273,652. The business’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.03. Kronos Bio has a 52 week low of $0.69 and a 52 week high of $1.60. The firm has a market cap of $58.49 million, a PE ratio of -0.55 and a beta of 1.87.

Kronos Bio (NASDAQ:KRONGet Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $2.69 million for the quarter, compared to analyst estimates of $1.75 million. Kronos Bio had a negative net margin of 1,222.83% and a negative return on equity of 68.82%. Equities analysts predict that Kronos Bio will post -1.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $2.25 price objective on shares of Kronos Bio in a research note on Monday, August 19th. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 price objective on shares of Kronos Bio in a research report on Tuesday, October 8th.

View Our Latest Stock Report on KRON

Institutional Trading of Kronos Bio

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Kronos Bio in the first quarter valued at approximately $71,000. Marquette Asset Management LLC boosted its holdings in shares of Kronos Bio by 19.8% in the 1st quarter. Marquette Asset Management LLC now owns 80,369 shares of the company’s stock valued at $104,000 after purchasing an additional 13,269 shares in the last quarter. Forefront Analytics LLC increased its stake in shares of Kronos Bio by 75.0% in the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock valued at $167,000 after purchasing an additional 57,867 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Kronos Bio by 17.2% during the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock worth $1,005,000 after buying an additional 113,618 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Kronos Bio by 14.6% during the 1st quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after buying an additional 247,918 shares during the last quarter. 64.09% of the stock is owned by institutional investors and hedge funds.

About Kronos Bio

(Get Free Report)

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.

Featured Articles

Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.